PA
BIIB icon

Pinnacle Associates’s Biogen BIIB Stock Holding History

Pinnacle Associates’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$733K Sell
3,999
-156
-4% -$28.7K 0.01% 579
2025
Q4 		$731K Buy
4,155
+7
+0.2% +$1.14K 0.01% 581
2025
Q3 		$581K Sell
4,148
-371
-8% -$50.1K 0.01% 611
2025
Q2 		$568K Buy
4,519
+102
+2% +$12.7K 0.01% 612
2025
Q1 		$604K Buy
4,417
+163
+4% +$23.3K 0.01% 576
2024
Q4 		$651K Sell
4,254
-303
-7% -$51.1K 0.01% 555
2024
Q3 		$1.18M Sell
4,557
-73
-2% -$15.3K 0.02% 442
2024
Q2 		$1.07M Sell
4,630
-131
-3% -$28.5K 0.02% 456
2024
Q1 		$1.03M Buy
4,761
+204
+4% +$47.8K 0.02% 474
2023
Q4 		$1.18M Buy
4,557
+16
+0.4% +$3.93K 0.02% 449
2023
Q3 		$1.17M Buy
4,541
+112
+3% +$30K 0.02% 432
2023
Q2 		$1.26M Buy
4,429
+10
+0.2% +$2.98K 0.02% 433
2023
Q1 		$1.23M Sell
4,419
-188
-4% -$52K 0.03% 379
2022
Q4 		$1.28M Buy
4,607
+5
+0.1% +$1.41K 0.03% 365
2022
Q3 		$1.23M Buy
4,602
+67
+1% +$14.2K 0.03% 362
2022
Q2 		$925K Buy
4,535
+25
+0.6% +$5.11K 0.02% 423
2022
Q1 		$950K Sell
4,510
-972
-18% -$211K 0.02% 450
2021
Q4 		$1.31M Buy
5,482
+76
+1% +$19.5K 0.02% 405
2021
Q3 		$1.53M Buy
5,406
+764
+16% +$250K 0.03% 377
2021
Q2 		$1.61M Sell
4,642
-892
-16% -$270K 0.03% 364
2021
Q1 		$1.55M Sell
5,534
-315
-5% -$85K 0.03% 360
2020
Q4 		$1.43M Sell
5,849
-597
-9% -$154K 0.03% 347
2020
Q3 		$1.83M Buy
6,446
+7
+0.1% +$1.95K 0.04% 290
2020
Q2 		$1.72M Buy
6,439
+294
+5% +$88.4K 0.04% 291
2020
Q1 		$1.94M Buy
6,145
+171
+3% +$51.9K 0.06% 255
2019
Q4 		$1.77M Sell
5,974
-2,845
-32% -$789K 0.04% 325
2019
Q3 		$2.05M Buy
8,819
+142
+2% +$33.1K 0.05% 302
2019
Q2 		$2.03M Sell
8,677
-4,089
-32% -$944K 0.05% 301
2019
Q1 		$3.02M Sell
12,766
-192
-1% -$60.5K 0.07% 257
2018
Q4 		$3.9M Sell
12,958
-1,006
-7% -$321K 0.1% 217
2018
Q3 		$4.93M Sell
13,964
-944
-6% -$325K 0.1% 215
2018
Q2 		$4.33M Sell
14,908
-219
-1% -$61.6K 0.09% 233
2018
Q1 		$4.14M Buy
15,127
+1,784
+13% +$554K 0.08% 233
2017
Q4 		$4.25M Buy
13,343
+4,091
+44% +$1.31M 0.08% 229
2017
Q3 		$2.9M Sell
9,252
-63
-0.7% -$18.7K 0.05% 264
2017
Q2 		$2.53M Buy
9,315
+162
+2% +$42.8K 0.05% 278
2017
Q1 		$2.5M Sell
9,153
-1,515
-14% -$428K 0.05% 285
2016
Q4 		$3.02M Sell
10,668
-1,210
-10% -$359K 0.06% 261
2016
Q3 		$3.72M Buy
11,878
+17
+0.1% +$5.04K 0.07% 235
2016
Q2 		$2.87M Sell
11,861
-65
-0.5% -$17.1K 0.06% 258
2016
Q1 		$3.1M Buy
11,926
+25
+0.2% +$6.6K 0.07% 240
2015
Q4 		$3.65M Buy
11,901
+479
+4% +$138K 0.08% 219
2015
Q3 		$3.33M Buy
11,422
+2,663
+30% +$879K 0.07% 227
2015
Q2 		$3.54M Buy
8,759
+2,294
+35% +$921K 0.07% 232
2015
Q1 		$2.73M Sell
6,465
-384
-6% -$151K 0.05% 259
2014
Q4 		$2.33M Buy
6,849
+45
+0.7% +$14.6K 0.05% 266
2014
Q3 		$2.25M Sell
6,804
-75
-1% -$24.7K 0.05% 272
2014
Q2 		$2.17M Sell
6,879
-332
-5% -$99.9K 0.04% 277
2014
Q1 		$2.21M Buy
7,211
+575
+9% +$183K 0.04% 269
2013
Q4 		$1.85M Buy
6,636
+120
+2% +$31K 0.04% 300
2013
Q3 		$1.57M Buy
6,516
+935
+17% +$209K 0.03% 303
2013
Q2 		$1.2M Buy
+5,581
New +$1.19M 0.03% 320

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Pinnacle Associates's BIIB Position: Q1 2026 in Review

Pinnacle Associates reduced its Biogen (BIIB) stake by 3.8% in Q1 2026, selling an estimated $28.7K and leaving 3,999 shares worth $733K. The position accounts for 0.01% of the portfolio, ranked #579.

Pinnacle Associates first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.93M in Q3 2018. 1,004 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Pinnacle Associates held 3,999 shares of Biogen worth $733K as of Q1 2026.
  • Pinnacle Associates sold 156 Biogen shares in Q1 2026, an estimated $28.7K.
  • Biogen made up 0.01% of Pinnacle Associates's portfolio in Q1 2026, its #579 holding.
  • Pinnacle Associates first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
  • Pinnacle Associates's Biogen position peaked at $4.93M in Q3 2018.
  • 1,004 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Pinnacle Associates's 13F filing for Q1 2026, filed 22 Apr 2026.